Interestingly, this genomic deletion frequently involves also an adjacent metabolic gene (methylthioadenosine phosphorylase, MTAP), thus generating a targetable vulnerability, which can be exploited therapeutically against MM, as we have recently suggested [17]. This evidence concerns the gene MTAP and Miyoshi myopathy.